<DOC>
	<DOCNO>NCT02596399</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , single-ascending dose study healthy volunteer , enrol single site United States investigate safety , tolerability , pharmacokinetics DSTA4637S .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics DSTA4637S Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Signed Informed Consent Form Able comply study protocol , investigator 's judgment Body mass index ( BMI ) 18 32 kilogram per square meter ( kg/m^2 ) , inclusive In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Clinical laboratory evaluation within reference range test laboratory unless deem clinically significant investigator Sponsor Willing abstain use drug abuse completion study Willing abstain use counter , herbal prescription medications/products 14 day prior Day 1 completion study , unless deem acceptable investigator Sponsor Agreeable , deem able ( investigator ) , comply requirement study , include followup period Willing abstain consumption alcoholbased product 72 hour prior Day 1 Phase 1 unit checkout Day 3 72 hour prior followup visit For woman childbearing potential , agreement remain abstinent ( refrain heterosexual intercourse ) use nonhormonal contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 85 day last dose study drug For men , agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm , define study protocol Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition opinion investigator Sponsor contraindicate use investigational drug may affect interpretation result render subject high risk treatment complication Use tobacco , electronic cigarette , personal vaporizer electronic nicotine delivery system ( positive history within 3 month initiation dose Day 1 ) Received vaccine within 14 day prior screen Pregnant lactating , intend become pregnant within 3 month screen Positive serum pregnancy test result screen Day &amp; # 8722 ; 1 Received oral antibiotic within 4 week initiation dose Day 1 , intravenous antibiotic within 8 week initiation dose Hospitalization within 4 week initiation dose Positive hepatitis C virus ( HCV ) antibody , hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ) antibody History significant drug abuse within 1 year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine , crack ) within 1 year prior screen Positive drug screen screen Day 1 History anaphylactic hypersensitivity drug reaction , unless approve investigator Sponsor Blood transfusion within 8 week prior screen History malignancy within 10 year screen except completely excise basal cell carcinoma squamous cell carcinoma skin Donation plasma ( great equal [ &gt; = ] 500 milliliter [ mL ] ) within 7 day prior study drug administration Donation loss whole blood ( exclude volume blood drawn screen procedure ) follow : 50499 mL whole blood within 30 day great ( &gt; ) 499 mL whole blood within 56 day prior study drug administration Hemoglobin &lt; 128 gram per liter ( g/L ) ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) screen Poor peripheral venous access History presence abnormal ECG clinically significant investigator 's opinion , include complete leave bundle branch block , second thirddegree heart block , evidence prior myocardial infarction Exposure biological therapy investigational biological agent within 90 day prior screen evaluation receive investigational treatment 30 day prior screen evaluation ( within 5 halflives investigational product , whichever great ) Any history hypersensitivity allergy rifampin rifamycin analog</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>DSTA4637S</keyword>
</DOC>